Serina Therapeutics (SER) Cash from Discontinued Operations (2020 - 2021)
Serina Therapeutics (SER) posted Cash from Discontinued Operations of 90000.0 for Q1 2021, up 2.17% sequentially from 92000.0 in Q2 2020, and down 151.14% YoY from 176000.0 in Q1 2020.
Serina Therapeutics (SER) Cash from Discontinued Operations (2020 - 2021) Analysis & Trends
Serina Therapeutics has reported Cash from Discontinued Operations for 2 years, with the latest figure at 90000.0 in Q1 2021.
- Quarterly Cash from Discontinued Operations fell 151.14% year-over-year to 90000.0 in Q1 2021, while the trailing twelve-month figure through Dec 2021 was 90000.0 (changed N/A YoY) and the FY2021 annual result came in at 90000.0, down 147.12% from the prior year.
- Cash from Discontinued Operations rose to 90000.0 in Q1 2021 per SER's latest filing, from 92000.0 in the prior quarter.
- Over five years, Cash from Discontinued Operations peaked at 176000.0 in Q1 2020 and troughed at 92000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Serina Therapeutics | 46.70 Mn | 23.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | -90,000.00 |
| Mar 31, 2021 | -90,000.00 |
| Jun 30, 2020 | -92,000.00 |
| Jun 30, 2020 | -92,000.00 |
| Mar 31, 2020 | 176,000.00 |
| Mar 31, 2020 | 176,000.00 |